Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RGS12 | O14924 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544895 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KDM4EHPGDKMT2AHSD17B10 | |
| SCHEMBL1544564 | 0.81 | ALDH1A1 (0.70) | ALDH1A1KDM4EHPGDCYP1A2CYP2C9 | |
| SCHEMBL10916439 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCYP1A2CYP2C9 | |
| SCHEMBL4172596 | 0.81 | ALDH1A1 (0.70) | ALDH1A1DRD2KDM4EHPGDCYP1A2 | |
| SCHEMBL1545223 | 0.81 | TSHR (0.59) | ALDH1A1KDM4EKMT2AGAAL3MBTL1 | |
| SCHEMBL822698 | 0.81 | HSD11B1 (0.68) | ALDH1A1DRD2KMT2AL3MBTL1TSHR | |
| SCHEMBL9224636 | 0.80 | DRD2 (0.77) | ALDH1A1DRD2KDM4EHPGDCYP1A2 | |
| SCHEMBL9223454 | 0.80 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDCYP1A2CYP2C9 | |
| SCHEMBL10915111 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDKMT2AHSD17B10 | |
| SCHEMBL4197148 | 0.78 | NPC1 (0.81) | DRD2KMT2AL3MBTL1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150184307-A1 | SILVER ELECTROPLATING SOLUTION | DAIWA FINE CHEMICALS CO., LTD. (LABORATORY) (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2881497-A1 | ELECTROSILVER PLATING FLUID | Daiwa Fine Chemicals Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-1994030-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070284258-A1 | Method For Silver Plating | DAIWA FINE CHEMICALS CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007100646-A1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-0495226-B1 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMA (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5260450-A | Anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5158968-A | 3-aryl-5-alkylthio-4H-1,2,4-traizoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5143933-A | Anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0495226-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | ALDH1A1 1944/4885DRD2 4695/4885KDM4E 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.